Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Retinoid receptor ligands act on retinoic acid receptors (RARs) and retinoid X receptors (RXRs). Both are nuclear receptors with α, β and γ subtypes that bind DNA as RAR-RXR heterodimers and regulate gene transcription. A receptor for the morphogen retinoic acid was identified in 1987 as a member of the nuclear receptor family. In 1990 a second receptor responding to retinoic acid, later named RXRα, revealed a distinct retinoid pathway. Tretinoin, the all-trans form of retinoic acid, activates RARs, while tamibarotene and AM 580 favor RARα and CD 437 favors RARγ. Adapalene, tazarotene, acitretin and fenretinide are synthetic retinoids, whereas bexarotene is a ligand selective for RXRs.
ZSH-2208 is a retinoic acid A analog that exhibits potent antitumor activity against tumor regenerative stem cells (TRCs) in esophageal squamous cell carcinoma (ESCC). Its mechanism of action involves the RARγ–TNFAIP3 signaling pathway.
Viaminate is a potent RAR/RXR activator, functioning as a derivative of Retinoic acid. It plays a crucial role in regulating gene expression involved in cellular differentiation and proliferation. This compound is primarily utilized in research on severe acne and various keratinization disorders, providing insights into the underlying molecular mechanisms and potential therapeutic avenues.
BRF110 is a selective, orally active rexinoid that targets the Nurr1-Retinoid X Receptor alpha (RXRα) heterodimer, exhibiting an EC50 of 0.9 μM in SH-SY5Y cells. This compound upregulates brain-derived neurotrophic factor (BDNF) expression and demonstrates neuroprotective effects against MPP+-induced toxicity. Notably, BRF110 is capable of crossing the blood-brain barrier, making it a valuable tool for research in neurobiology and potential therapeutic applications in neurodegenerative diseases.
TBTC is a selective retinoic acid receptor (RAR) and retinoid X receptor (RXR) activator. It demonstrates notable effects in improving behavioral deficits in Alzheimer's disease model mice, enhancing the activation of heterodimers formed by RXRα with LXRα or PPARγ. TBTC promotes the expression of key genes including apoE, ABCA1, and ABCG1, while effectively reducing amyloid-beta (Aβ) levels in cellular and animal studies, making it a valuable tool for Alzheimer’s research.
NRX-204647 is a selective retinoic acid receptor gamma (RARγ) activator that exhibits high specificity compared to RARα and RARβ. This compound demonstrates significant biological activity in inhibiting bone formation, as evidenced by its ability to reduce bone volume/tissue volume (BV/TV). NRX-204647 is a valuable tool for investigating mechanisms in anti-cancer research and elucidating the role of RARγ in various biological processes.
BMS-185354 is a selective retinoic acid receptor gamma (RARγ) activator, exhibiting an EC50 value of 28 nM. This compound plays a significant role in modulating gene expression involved in various biological processes. BMS-185354 is primarily utilized in cancer research to investigate the therapeutic potential of targeting RARγ pathways in oncogenesis and tumor progression.
Out of stock
All 3 sizes